Modulation of Mesenchymal Stem Cells-Mediated Adaptive Immune Effectors' Repertoire in the Recovery of Systemic Lupus Erythematosus
- PMID: 36272020
- DOI: 10.1007/s12015-022-10452-7
Modulation of Mesenchymal Stem Cells-Mediated Adaptive Immune Effectors' Repertoire in the Recovery of Systemic Lupus Erythematosus
Abstract
The breakdown of self-tolerance of the immune response can lead to autoimmune conditions in which chronic inflammation induces tissue damage. Systemic lupus erythematosus (SLE) is a debilitating multisystemic autoimmune disorder with a high prevalence in women of childbearing age; however, SLE incidence, prevalence, and severity are strongly influenced by ethnicity. Although the mystery of autoimmune diseases remains unsolved, disturbance in the proportion and function of B cell subsets has a major role in SLE's pathogenesis. Additionally, colocalizing hyperactive T helper cell subgroups within inflammatory niches are indispensable. Despite significant advances in standard treatments, nonspecific immunosuppression, the risk of serious infections, and resistance to conventional therapies in some cases have raised the urgent need for new treatment strategies. Without the need to suppress the immune system, mesenchymal stem cells (MSCs), as ''smart" immune modulators, are able to control cellular and humoral auto-aggression responses by participating in precursor cell development. In lupus, due to autologous MSCs disorder, the ability of allogenic engrafted MSCs in tissue regeneration and resetting immune homeostasis with the provision of a new immunocyte repertoire has been considered simultaneously. In Brief The bone marrow mesenchymal stem cells (BM-MSCs) lineage plays a critical role in maintaining the hematopoietic stem-cell microstructure and modulating immunocytes. The impairment of BM-MSCs and their niche partially contribute to the pathogenesis of SLE-like diseases. Allogenic MSC transplantation can reconstruct BM microstructure, possibly contributing to the recovery of immunocyte phenotype restoration of immune homeostasis. In terms of future prospects of MSCs, artificially gained by ex vivo isolation and culture adaptation, the wide variety of potential mediators and mechanisms might be linked to the promotion of the immunomodulatory function of MSCs.
Keywords: Acquired immune system, Lymphocyte repertoire; Mesenchymal stem cells; Systemic lupus erythematosus.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Dysregulated balance in Th17/Treg axis of Pristane-induced lupus mouse model, are mesenchymal stem cells therapeutic?Int Immunopharmacol. 2023 Apr;117:109699. doi: 10.1016/j.intimp.2023.109699. Epub 2023 Mar 1. Int Immunopharmacol. 2023. PMID: 36867923
-
Multipotent Mesenchymal Stromal Cells in Rheumatoid Arthritis and Systemic Lupus Erythematosus; From a Leading Role in Pathogenesis to Potential Therapeutic Saviors?Front Immunol. 2021 Feb 24;12:643170. doi: 10.3389/fimmu.2021.643170. eCollection 2021. Front Immunol. 2021. PMID: 33732263 Free PMC article. Review.
-
Combined transplantation of autologous hematopoietic stem cells and allogenic mesenchymal stem cells increases T regulatory cells in systemic lupus erythematosus with refractory lupus nephritis and leukopenia.Lupus. 2015 Oct;24(11):1221-6. doi: 10.1177/0961203315583541. Epub 2015 Apr 24. Lupus. 2015. PMID: 25914407
-
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus.Arthritis Rheum. 2010 Sep;62(9):2776-86. doi: 10.1002/art.27560. Arthritis Rheum. 2010. PMID: 20496367
-
Prospects for the Application of Transplantation With Human Amniotic Membrane Epithelial Stem Cells in Systemic Lupus Erythematosus.Cell Transplant. 2024 Jan-Dec;33:9636897241236586. doi: 10.1177/09636897241236586. Cell Transplant. 2024. PMID: 38469823 Free PMC article. Review.
Cited by
-
A new generation of mesenchymal stromal/stem cells differentially trained by immunoregulatory probiotics in a lupus microenvironment.Stem Cell Res Ther. 2023 Dec 10;14(1):358. doi: 10.1186/s13287-023-03578-z. Stem Cell Res Ther. 2023. PMID: 38072921 Free PMC article.
-
A review on mesenchymal stem cells and their secretome in hepatocellular carcinogenesis and its related signaling pathways: recent update.Discov Oncol. 2025 Jul 7;16(1):1276. doi: 10.1007/s12672-025-03088-9. Discov Oncol. 2025. PMID: 40622501 Free PMC article. Review.
-
Pulse Activation of Retinoic Acid Receptor Enhances Hematopoietic Stem Cell Homing by Controlling CXCR4 Membrane Presentation.Stem Cell Rev Rep. 2025 Jan;21(1):68-79. doi: 10.1007/s12015-024-10813-4. Epub 2024 Oct 31. Stem Cell Rev Rep. 2025. PMID: 39480614
-
Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights.Stem Cell Res Ther. 2025 Feb 4;16(1):33. doi: 10.1186/s13287-025-04158-z. Stem Cell Res Ther. 2025. PMID: 39901306 Free PMC article. Review.
References
-
- Kapsogeorgou, E. K., & Tzioufas, A. G. (2016). Autoantibodies in autoimmune diseases: Clinical and critical evaluation. The Israel Medical Association Journal: IMAJ, 18(9), 519–524.
-
- Rezaieyazdi, Z., et al. (2021). Outcomes of planned pregnancy in patients with systemic lupus erythematosus and their neonates. The Egyptian Rheumatologist, 43(2), 141–145.
-
- Wang, L., Wang, F. S., & Gershwin, M. E. (2015). Human autoimmune diseases: A comprehensive update. Journal of internal medicine, 278(4), 369–395.
-
- Ray, S., et al. (2012). Autoimmune disorders: An overview of molecular and cellular basis in today’s perspective. Journal of Clinical & Cellular Immunology, 10(003), 2215–2230.
-
- Stojan, G., & Petri, M. (2018). Epidemiology of systemic lupus erythematosus: An update. Current opinion in rheumatology, 30(2), 144.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical